1985 and 1986 were milestones for those who study atherosclerosis. In those years took place the USA Consensus Conference, followed first by the Italian Consensus Conference and then by the European one. They marked the final solution to the "querelle" on cholesterol and ischemic cardiopathy. On the basis of the results obtained from the Coronary Primary Prevention Trial (CPPT), plasmatic cholesterol is now no longer considered "a" risk factor in cardiovas cular diseases, but "the cause" of atherosclerosis and its organ damages. This was also the basic statement that came out of the 6th…mehr
1985 and 1986 were milestones for those who study atherosclerosis. In those years took place the USA Consensus Conference, followed first by the Italian Consensus Conference and then by the European one. They marked the final solution to the "querelle" on cholesterol and ischemic cardiopathy. On the basis of the results obtained from the Coronary Primary Prevention Trial (CPPT), plasmatic cholesterol is now no longer considered "a" risk factor in cardiovas cular diseases, but "the cause" of atherosclerosis and its organ damages. This was also the basic statement that came out of the 6th International Congress on "Atherosclerosis and Cardiovascular Diseases". The meeting was attended by specialists from various countries representing different experimental ap proaches to the cardiovascular diseases, from basic research (receptor pathol ogy, apoproteins physiopathology); to epidemiology (both observational study and prevention); to pure cardiology in its aspects of physiopathology, diagnosis and therapy; to the new invasive and non-invasive diagnostic methods; and to the presentation of studies which correlate new variables (serotonin, en dogenous opioids) with the atheromasic disease. The final outcome of this re search is therapy, be it a pharmacological, nutritional and/or surgical one. Il lustrious names from five continents dealt with a wide a range of topics, and their presentations produced a wealth of data. The presentations contained in this volume are the "corpus" of the congress and will serve as a precise updat ing for all specialists, physicians and students.
Evaluation of the clinical significance of the discovery of the LDL receptor.- 1. Evaluation of the clinical significance of the discovery of the LDL receptor.- Social aspects of atherosclerosis.- 2. Social aspects of atherosclerosis.- Primary and secondary prevention of atherosclerosis and coronary heart disease.- 3. Primary and secondary prevention of atherosclerosis and coronary heart disease.- The "CNR Progetto Finalizzato Obiettivo 44 Progressione e/o regression" an update on studies in Italy.- 4. The "CNR Progetto Finalizzato Obiettivo 44 Progressione e/o regression" an update on studies in Italy.- Atherosclerosis and the "CNR Progetto Finalizzato Medicina Preventiva e Riabilitativa".- 5. Atherosclerosis and the "CNR Progetto Finalizzato Medicina Preventiva e Riabilitativa".- Cardiac and vascular surgery: results, perspectives and hopes.- 6. Cardiac and vascular surgery: results, perspectives and hopes.- Apoproteins - Clinical Aspects.- 7. Genetic basis of apolipoprotein disorders.- 8. Apolipoproteins in differential diagnosis of patients at high risk for atherosclerosis.- 9. Genetic and non-genetic control of apoprotein metabolism in cultured human cells.- 10. The plasma metabolism of apolipoprotein A-IV.- 11. Modified LDL in humans.- 12. Clinical aspects of lipoprotein disorders.- Fixed Versus Dynamic Stenosis: Possible Causes and Therapeutic Approaches.- 13. Fixed versus dynamic stenosis: possible causes and therapeutic approach.- 14. The epicardial coronary arteries at necropsy in acute myocardial infarction.- 15. Perspectives in the management of acute myocardial infarction.- 16. Atherosclerosis and ischaemic heart disease: surgical solutions.- Present Knowledge and Perspectives of Calcium Entry Blockers in the Management of Coronary Artery Disease.- 17. Effects of calcium antagonists and adrenergic antihypertensive drugs on cellular cholesterol metabolism.- 18. Blood platelets: their role in atherogenesis and arterial thrombosis and their inhibition, in particular by calcium antagonists.- Primary and Secondary Prevention: Different Experiences.- 19. Prevention of coronary heart disease - links with other chronic disorders.- 20. Therapy versus prevention of coronary heart disease.- 21. Prevention in Europe - facts, fallacies and future.- 22. Low linoleic acid - a new risk factor for coronary heart disease.- 23. The US National Cholesterol Education Program.- 24. The WHO European Multifactor Preventive Trial of CHD.- 25. Epidemiology and clinical features of hypertension in the elderly.- 26. Atherosclerosis precursors in children. The Bologna study. Preliminary data.- 27. From observational to intervention programmes. The Brisighella study.- Lipid Regulation in the Prevention of Coronary Heart Disease.- 28. Relationship of glucose intolerance and elevated triglyceride: implications for gemfibrozil.- 29. A comparison of different formulations and dosage administrations of gemfibrozil in types IIA and IIB hyperlipidemia.- 30. Coronary heart disease in Italy.- Diet: A Risk Factor and a Means of Prevention of Atherosclerosis and Coronary Heart Disease.- 31. Dietary fiber and lipid metabolism.- 32. Dietary and biochemical studies with textured soy proteins.- 33. Fats from marine animals in human nutrition and prevention of cardiovascular diseases.- 34. The influence of diet and drugs of cholesterol metabolism in the liver.- 35. Individuality of the response of serum cholesterol to dietary cholesterol.- 36. Familial hypercholesterolemia in Italy; plasma cholesterol evaluation and diagnostic insight.- Extra Coronary Atherosclerotic Vascular Diseases.- 37. Do atherosclerotic plaques regress spontaneously in humans?.- 38. Pathogenetic mechanisms of transient brain ischaemic attacks.- 39. Interrelations between the degree of lipid lowering effect and the rate of progression of atherosclerotic cardiovascular disease.- 40. Results of carotid endarterectomy.- New Technologies and New Diagnostic and Therapeutic Approaches to Card
Evaluation of the clinical significance of the discovery of the LDL receptor.- 1. Evaluation of the clinical significance of the discovery of the LDL receptor.- Social aspects of atherosclerosis.- 2. Social aspects of atherosclerosis.- Primary and secondary prevention of atherosclerosis and coronary heart disease.- 3. Primary and secondary prevention of atherosclerosis and coronary heart disease.- The "CNR Progetto Finalizzato Obiettivo 44 Progressione e/o regression" an update on studies in Italy.- 4. The "CNR Progetto Finalizzato Obiettivo 44 Progressione e/o regression" an update on studies in Italy.- Atherosclerosis and the "CNR Progetto Finalizzato Medicina Preventiva e Riabilitativa".- 5. Atherosclerosis and the "CNR Progetto Finalizzato Medicina Preventiva e Riabilitativa".- Cardiac and vascular surgery: results, perspectives and hopes.- 6. Cardiac and vascular surgery: results, perspectives and hopes.- Apoproteins - Clinical Aspects.- 7. Genetic basis of apolipoprotein disorders.- 8. Apolipoproteins in differential diagnosis of patients at high risk for atherosclerosis.- 9. Genetic and non-genetic control of apoprotein metabolism in cultured human cells.- 10. The plasma metabolism of apolipoprotein A-IV.- 11. Modified LDL in humans.- 12. Clinical aspects of lipoprotein disorders.- Fixed Versus Dynamic Stenosis: Possible Causes and Therapeutic Approaches.- 13. Fixed versus dynamic stenosis: possible causes and therapeutic approach.- 14. The epicardial coronary arteries at necropsy in acute myocardial infarction.- 15. Perspectives in the management of acute myocardial infarction.- 16. Atherosclerosis and ischaemic heart disease: surgical solutions.- Present Knowledge and Perspectives of Calcium Entry Blockers in the Management of Coronary Artery Disease.- 17. Effects of calcium antagonists and adrenergic antihypertensive drugs on cellular cholesterol metabolism.- 18. Blood platelets: their role in atherogenesis and arterial thrombosis and their inhibition, in particular by calcium antagonists.- Primary and Secondary Prevention: Different Experiences.- 19. Prevention of coronary heart disease - links with other chronic disorders.- 20. Therapy versus prevention of coronary heart disease.- 21. Prevention in Europe - facts, fallacies and future.- 22. Low linoleic acid - a new risk factor for coronary heart disease.- 23. The US National Cholesterol Education Program.- 24. The WHO European Multifactor Preventive Trial of CHD.- 25. Epidemiology and clinical features of hypertension in the elderly.- 26. Atherosclerosis precursors in children. The Bologna study. Preliminary data.- 27. From observational to intervention programmes. The Brisighella study.- Lipid Regulation in the Prevention of Coronary Heart Disease.- 28. Relationship of glucose intolerance and elevated triglyceride: implications for gemfibrozil.- 29. A comparison of different formulations and dosage administrations of gemfibrozil in types IIA and IIB hyperlipidemia.- 30. Coronary heart disease in Italy.- Diet: A Risk Factor and a Means of Prevention of Atherosclerosis and Coronary Heart Disease.- 31. Dietary fiber and lipid metabolism.- 32. Dietary and biochemical studies with textured soy proteins.- 33. Fats from marine animals in human nutrition and prevention of cardiovascular diseases.- 34. The influence of diet and drugs of cholesterol metabolism in the liver.- 35. Individuality of the response of serum cholesterol to dietary cholesterol.- 36. Familial hypercholesterolemia in Italy; plasma cholesterol evaluation and diagnostic insight.- Extra Coronary Atherosclerotic Vascular Diseases.- 37. Do atherosclerotic plaques regress spontaneously in humans?.- 38. Pathogenetic mechanisms of transient brain ischaemic attacks.- 39. Interrelations between the degree of lipid lowering effect and the rate of progression of atherosclerotic cardiovascular disease.- 40. Results of carotid endarterectomy.- New Technologies and New Diagnostic and Therapeutic Approaches to Card
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309